Diligence memo · auto-generated · as of July 2, 2026
Denali Therapeutics Inc.
Denali Therapeutics Inc. has raised $500M over 1 round; too few niche peers to rank its valuation yet.
Businessfiled
Denali Therapeutics Inc. operates in Biotechnology, based in SOUTH SAN FRANCISCO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Denali Therapeutics Inc. has raised $500M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $500M on 2024-02-29.
Most recent recorded round closed around 2024-02-29.
Valuation (modeled)modeled
Provath models Denali Therapeutics Inc. at approximately $7.2B (range $3.1B–$9.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Last raise 2.3 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 99% of Biotechnology peers (4293 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: ImmunityBio, Inc., Avidity Biosciences, Inc., Inhibrx, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.